Hamari PFST, Ltd. – FDA 483, Nov 10, 2023
The FDA conducted an inspection of Hamari PFST, Ltd., an Active Pharmaceutical Ingredient (API) manufacturer located in Yonezawa, Yamagata, Japan, from November 6-10, 2023. During this inspection, two significant observations were noted regarding Good Manufacturing Practices (GMP).
The first observation detailed a lack of established written procedures for cleaning manufacturing equipment and its subsequent release for use. Specifically, the company did not provide scientific rationale for implementing new batch cleaning procedures for an intermediate, failing to assess whether cleaning validation or verification was needed, how equipment would be protected prior to use, and how its cleanliness would be verified immediately before use.
The second observation highlighted deficiencies in record-keeping practices. On July 3, 2023, cleaning documents were not made available to operators in a manufacturing building, which led to delayed entries. Procedures performed on July 3-4, 2023, were only recorded on July 5, 2023. This issue affects the integrity and accuracy of crucial manufacturing records.
These findings indicate a need for Hamari PFST, Ltd. to develop and implement robust procedural controls and ensure timely and accurate documentation to meet regulatory expectations for pharmaceutical manufacturing quality and safety.
ID · 07eb0e3d-39a5-4a97-a43f-b2dffc5cf2e0
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.